USFDA accepts Blenrep combinations for treatment of relapsed/refractory multiple myeloma

If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse

AstraZeneca Pharma Pharma India to launch Breztri Aerosphere in Jan 2025

IMCD expands its Pharmaceuticals Technical Centre in Jakarta

The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards

Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer

The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024

JHU signs MoU with Ajit Isaac Foundation to bring essential palliative care services to rural India’s terminally ill

The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation

Sartorius Stedim Biotech opens center for bioprocess innovation in USA

New research labs and process development services to enable next generation therapeutics

Azenta obtains regulatory approval for clinical long-read whole genome sequencing test

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory

Strides Pharma Science appoints Dr. C. Muthulingam as Executive VP - R&D

Dr. Muthu was last associated with Mankind Pharma

Merck Life Science India ink MoU with GeNext Genomics

Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem

European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors

HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors